MCID: NNT008
MIFTS: 37

Neonatal Abstinence Syndrome malady

Categories: Respiratory diseases, Mental diseases

Aliases & Classifications for Neonatal Abstinence Syndrome

Summaries for Neonatal Abstinence Syndrome

Disease Ontology : 12 A withdrawal disorder that is characterized by a group of problems that occur in a newborn who was exposed to addictive illegal or prescription drugs while in the mother's womb or postnatally following the discontinuance of drug treatment.

MalaCards based summary : Neonatal Abstinence Syndrome, also known as drug withdrawal syndrome in newborn, is related to encephalopathy and c8 deficiency, type ii. An important gene associated with Neonatal Abstinence Syndrome is OPRM1 (Opioid Receptor Mu 1), and among its related pathways/superpathways are Peptide ligand-binding receptors and Interleukin-4 and 13 signaling. The drugs Clonidine and Morphine have been mentioned in the context of this disorder. Affiliated tissues include breast and heart, and related phenotypes are behavior/neurological and integument

Related Diseases for Neonatal Abstinence Syndrome

Graphical network of the top 20 diseases related to Neonatal Abstinence Syndrome:



Diseases related to Neonatal Abstinence Syndrome

Symptoms & Phenotypes for Neonatal Abstinence Syndrome

MGI Mouse Phenotypes related to Neonatal Abstinence Syndrome:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.35 COMT OPRD1 OPRK1 OPRM1 PNOC
2 integument MP:0010771 8.92 OPRD1 OPRK1 OPRM1 PNOC

Drugs & Therapeutics for Neonatal Abstinence Syndrome

Drugs for Neonatal Abstinence Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 66)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clonidine Approved Phase 4,Phase 2,Phase 3,Phase 1 4205-90-7 2803
2
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 57-27-2 5288826
3
Loperamide Approved Phase 4 53179-11-6 3955
4
Phenobarbital Approved Phase 4,Phase 3 50-06-6 4763
5
Methadone Approved Phase 4,Phase 2,Phase 3,Phase 1 76-99-3 4095
6
Clonazepam Approved, Illicit Phase 4 1622-61-3 2802
7
Opium Approved, Illicit Phase 4 8008-60-4
8
Guaifenesin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 93-14-1 3516
9
Benzocaine Approved Phase 4,Phase 3,Phase 2 1994-09-7, 94-09-7 2337
10 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 2
11 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
12 Adrenergic Agents Phase 4,Phase 2,Phase 3
13 Narcotics Phase 4,Phase 3,Phase 2,Phase 1
14 Adrenergic Agonists Phase 4,Phase 2,Phase 3
15 Adrenergic alpha-2 Receptor Agonists Phase 4,Phase 2,Phase 3
16 Adrenergic alpha-Agonists Phase 4,Phase 2,Phase 3
17 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
18 Sympatholytics Phase 4,Phase 2,Phase 3
19 Analgesics, Opioid Phase 4,Phase 3,Phase 2,Phase 1
20 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
21 Antihypertensive Agents Phase 4,Phase 2,Phase 3
22 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
23 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1
24 Chlorpheniramine, phenylpropanolamine drug combination Phase 4,Phase 3,Phase 2,Phase 1
25 GABA Agents Phase 4,Phase 3
26 GABA Modulators Phase 4,Phase 3
27 Gastrointestinal Agents Phase 4,Phase 3,Phase 1,Phase 2
28 Cytochrome P-450 CYP3A Inducers Phase 4,Phase 3
29 Hypnotics and Sedatives Phase 4,Phase 3
30 Excitatory Amino Acid Antagonists Phase 4,Phase 3
31 Excitatory Amino Acids Phase 4,Phase 3
32 Anticonvulsants Phase 4,Phase 3
33 Antidiarrheals Phase 4
34 Respiratory System Agents Phase 4,Phase 3,Phase 2,Phase 1
35 Antitussive Agents Phase 4,Phase 3,Phase 2,Phase 1
36 Opium Poppy Nutraceutical Phase 4
37
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
38
Cocaine Approved, Illicit Phase 2, Phase 3 50-36-2 5760 446220
39
Chlorpromazine Approved, Vet_approved Phase 3 50-53-3 2726
40
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 52485-79-7 40400 644073
41
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754 657311
42 Narcotic Antagonists Phase 3,Phase 2,Phase 1
43 Tranquilizing Agents Phase 3,Phase 1,Phase 2
44 Dopamine Agents Phase 3
45 Dopamine Antagonists Phase 3
46 Pharmaceutical Solutions Phase 3,Phase 1,Phase 2
47 Antiemetics Phase 3,Phase 1,Phase 2
48 Psychotropic Drugs Phase 3,Phase 1,Phase 2
49 Antipsychotic Agents Phase 3,Phase 1,Phase 2
50 Cortisol succinate Phase 3

Interventional clinical trials:

(show all 42)
id Name Status NCT ID Phase
1 NAS Treatment - Opiate Versus Non-Opiate Unknown status NCT01734551 Phase 4
2 Treatment of Neonatal Abstinence Syndrome Completed NCT01723722 Phase 4
3 Comparison Between Methadone and Morphine for Neonatal Opiate Withdrawal Completed NCT01804075 Phase 4
4 Treatment of Neonatal Abstinence Syndrome With Clonidine Versus Morphine as Primary Therapy Not yet recruiting NCT03092011 Phase 4
5 Morphine Versus Methadone for Opiate Exposed Infants With Neonatal Abstinence Syndrome Not yet recruiting NCT02851303 Phase 4
6 Blinded Trial of Buprenorphine or Morphine in the Treatment of the Neonatal Abstinence Syndrome Completed NCT01452789 Phase 3
7 Fetal and Infant Effects of Maternal Buprenorphine Treatment Completed NCT01561079 Phase 2, Phase 3
8 Maternal Acupuncture for Substance Abuse Completed NCT00225316 Phase 3
9 How to Treat Opiate Withdrawal in Neonates Completed NCT02810782 Phase 3
10 Tobacco Use in Opioid Agonist Treated Pregnant Women Completed NCT00497068 Phase 2, Phase 3
11 Recovery Housing For Drug Dependent Pregnant Women Completed NCT00497302 Phase 2, Phase 3
12 Improving Outcomes in Neonatal Abstinence Syndrome Active, not recruiting NCT01958476 Phase 3
13 The Effect of Aromatherapy on Neonatal Abstinence Syndrome and Salivary Cortisol Levels Enrolling by invitation NCT03097484 Phase 3
14 Clonidine to Treat Iatrogenic-induced Opioid Dependence in Infants Terminated NCT01360450 Phase 2, Phase 3
15 Clonidine as Adjunct Therapy for the Treatment of Neonatal Abstinence Syndrome Completed NCT00510016 Phase 2
16 RCT of High- vs. Standard-Calorie Formula for Methadone-Exposed Infants Completed NCT02178189 Phase 2
17 The Effects of Methadone and Buprenorphine on Fetal Neurobehavior and Infant Neonatal Abstinence Syndrome - 1 Completed NCT00218621 Phase 2
18 How Pregnant Women and Their Babies Metabolize Ondansetron Compared to a Group of Non-pregnant Women Completed NCT01801475 Phase 1, Phase 2
19 Can Ondansetron Prevent Neonatal Abstinence Syndrome (NAS) in Babies Born to Narcotic-dependent Women Recruiting NCT01965704 Phase 2
20 Methadone Demonstration Project Recruiting NCT03134703 Phase 2
21 Sublingual Buprenorphine Treatment for Neonatal Abstinence Syndrome - Pilot Study Recruiting NCT02249026 Phase 1, Phase 2
22 Comparison of Buprenorphine to Morphine in Treatment of Neonatal Abstinence Syndrome (NAS) Enrolling by invitation NCT01708707 Phase 2
23 Efficacy of Auricular Acupuncture on Neonatal Abstinence Syndrome Not yet recruiting NCT02872077 Phase 1, Phase 2
24 Buprenorphine for Treatment of Neonatal Abstinence Syndrome in Infants With In Utero Exposure to Benzodiazepines Completed NCT01671410 Phase 1
25 Buprenorphine for the Treatment of Neonatal Abstinence Syndrome Completed NCT00521248 Phase 1
26 The Pharmacokinetics of Oral Methadone in the Treatment of Neonatal Abstinence Syndrome Completed NCT01754324 Phase 1
27 Acupuncture in Neonatal Abstinence Syndrome (NAS) Babies Unknown status NCT02062151
28 Vagal Tone and Neonatal Abstinence Syndrome Completed NCT00496951
29 Utility of Psychosocial Intervention in Improving Outcome for Methadone-exposed Infants and Their Mothers Completed NCT01889121
30 RESPECT-PLUS: Services for Infants With Prenatal Opiate Exposure Completed NCT02334111
31 Fetal Neurobehavior in Poly-drug Dependent Women Completed NCT00653692
32 Fetal Neurobehavioral Development in Methadone Maintained Pregnancies Completed NCT00067184
33 The Effect of Fetal Gender on Maternal Substance Abuse Treatment Completed NCT00882648
34 Conflict Between Maternal Autonomy and Child Health in Substance-use Completed NCT02797990
35 Impact of Pregnancy on Buprenorphine Pharmacokinetics and Pharmacodynamics Recruiting NCT02863601
36 Opioid Dependence Treatment Therapies in Pregnancy Recruiting NCT03098407
37 Donor Human Milk in Neonatal Abstinence Syndrome Active, not recruiting NCT02182973
38 Physiology and Therapeutic Management of Neonatal Abstinence Syndrome Enrolling by invitation NCT02768844
39 Efficacy and Outcomes of a Non-Pharmacological Intervention for Neonatal Abstinence Syndrome Enrolling by invitation NCT02801331
40 Buprenorphine Dose Adjustments and Gestational Age Enrolling by invitation NCT03028883
41 Weighted Blankets With Infants With NAS Not yet recruiting NCT03113656
42 Clonidine for Neonatal Abstinence Syndrome Study Terminated NCT01175668

Search NIH Clinical Center for Neonatal Abstinence Syndrome

Cochrane evidence based reviews: neonatal abstinence syndrome

Genetic Tests for Neonatal Abstinence Syndrome

Anatomical Context for Neonatal Abstinence Syndrome

MalaCards organs/tissues related to Neonatal Abstinence Syndrome:

39
Breast, Heart

Publications for Neonatal Abstinence Syndrome

Articles related to Neonatal Abstinence Syndrome:

(show top 50) (show all 218)
id Title Authors Year
1
Association of maternal and infant variants in PNOC and COMT genes with neonatal abstinence syndrome severity. ( 27983768 )
2017
2
The opioid epidemic and neonatal abstinence syndrome in the USA: a review of the continuum of care. ( 28073819 )
2017
3
Neonatal Abstinence Syndrome and Ethical Approaches to the Identification of Pregnant Women Who Use Drugs. ( 27926654 )
2017
4
Special Issue on Neonatal Abstinence Syndrome. ( 27636689 )
2016
5
Predictors of neonatal abstinence syndrome in buprenorphine exposed newborn: can cord blood buprenorphine metabolite levels help? ( 27386303 )
2016
6
Effect of breastfeeding on neonatal abstinence syndrome. ( 27261233 )
2016
7
Active Somatic and Psychic Ear Acupuncture Points in Newborn Infants with Neonatal Abstinence Syndrome. ( 27486672 )
2016
8
The relationship between gestational age and the severity of neonatal abstinence syndrome. ( 27886650 )
2016
9
NANN Provides Education About Neonatal Abstinence Syndrome and Zika Virus Infection and Prepares Neonatal Nurses to Be Advocates for Their Profession and Their Patients. ( 27391568 )
2016
10
Rural and Urban Differences in Neonatal Abstinence Syndrome and Maternal Opioid Use, 2004 to 2013. ( 27942711 )
2016
11
Early Treatment for Neonatal Abstinence Syndrome: A Palliative Approach. ( 27907936 )
2016
12
A Qualitative Study of Family Experience With Hospitalization for Neonatal Abstinence Syndrome. ( 27647475 )
2016
13
Does Breast Milk Affect Neonatal Abstinence Syndrome Severity, the Need for Pharmacologic Therapy, and Length of Stay for Infants of Mothers on Opioid Maintenance Therapy During Pregnancy? ( 27564423 )
2016
14
Long-Term Outcomes of Infants with Neonatal Abstinence Syndrome. ( 27636691 )
2016
15
Comparison of Neonatal Abstinence Syndrome Manifestations in Preterm Versus Term Opioid-Exposed Infants. ( 27611018 )
2016
16
Neonatal Abstinence Syndrome: Twelve Years of Experience at a Regional Referral Center. ( 27723910 )
2016
17
Nonpharmacologic Management of Neonatal Abstinence Syndrome: An Integrative Review. ( 27636695 )
2016
18
The Association Between Breastfeeding and Length of Hospital Stay Among Infants Diagnosed with Neonatal Abstinence Syndrome: A Population-Based Study of In-Hospital Births. ( 27529500 )
2016
19
Incidence of Neonatal Abstinence Syndrome - 28 States, 1999-2013. ( 27513154 )
2016
20
Neonatal Abstinence Syndrome: A Growing Problem. ( 27636688 )
2016
21
A Cohort Comparison of Buprenorphine versus Methadone Treatment forA Neonatal Abstinence Syndrome. ( 26703873 )
2016
22
A core outcome set for neonatal abstinence syndrome: study protocol for a systematic review, parent interviews and a Delphi survey. ( 27821184 )
2016
23
Bringing attention to a need for a standardized treatment and weaning protocol for neonatal abstinence syndrome. ( 26835401 )
2016
24
Epidemiological Evidence for a Decreasing Incidence of Neonatal Abstinence Syndrome, 2000-11. ( 26849178 )
2016
25
Incidence of neonatal abstinence syndrome triples in US. ( 27528262 )
2016
26
Nonopioid Management of Neonatal Abstinence Syndrome. ( 28002062 )
2016
27
Neonatal Abstinence Syndrome in West Virginia Substate Regions, 2007-2013. ( 26879950 )
2016
28
Maternal opioid dose is associated with neonatal abstinence syndrome in children born to women with sickle cell disease. ( 26799428 )
2016
29
Monitoring Neonatal Abstinence Syndrome in buprenorphine-exposed IVF twins: A case study. ( 27163782 )
2016
30
Neonatal Abstinence Syndrome. ( 28002715 )
2016
31
Neonatal abstinence syndrome: Pharmacologic strategies for the mother and infant. ( 26791055 )
2016
32
Rooming-in for Infants at Risk of Neonatal Abstinence Syndrome. ( 26588259 )
2016
33
Pharmacotherapy for Neonatal Abstinence Syndrome: Choosing the Right Opioid or No Opioid at All. ( 27636696 )
2016
34
Role of Clonidine in Neonatal Abstinence Syndrome: A Systematic Review. ( 26783353 )
2016
35
Rates of Neonatal Abstinence Syndrome Amid Efforts to Combat the Opioid Abuse Epidemic. ( 27669331 )
2016
36
Neonatal Abstinence Syndrome: Presentation and Treatment Considerations. ( 26974659 )
2016
37
Measurement of neonatal abstinence syndrome: Evaluation of short forms. ( 26908300 )
2016
38
Improving Care for Neonatal Abstinence Syndrome. ( 27244809 )
2016
39
Neonatal Abstinence Syndrome: Presentation and Treatment Considerations. ( 27244045 )
2016
40
Neonatal Abstinence Syndrome Following Tianeptine Dependence During Pregnancy. ( 26659818 )
2016
41
Rooming-In to Treat Neonatal Abstinence Syndrome: Improved Family-Centered Care at Lower Cost. ( 27194629 )
2016
42
Neonatal abstinence syndrome and the gastrointestinal tract. ( 27876117 )
2016
43
NICU Culture of Care for Infants with Neonatal Abstinence Syndrome: A Focused Ethnography. ( 27636693 )
2016
44
Question: Is breastfeeding useful in the management of neonatal abstinence syndrome? ( 25784740 )
2015
45
Implementation of a statewide surveillance system for neonatal abstinence syndrome - Tennessee, 2013. ( 25674995 )
2015
46
Patterns of Disruptive Feeding Behaviors in Infants With Neonatal Abstinence Syndrome. ( 26308605 )
2015
47
Variations in opioid receptor genes in neonatal abstinence syndrome. ( 26233486 )
2015
48
Ondansetron pharmacokinetics in pregnant women and neonates: towards a new treatment for neonatal abstinence syndrome. ( 25670522 )
2015
49
Reply to 'Methadone versus morphine for treatment of neonatal abstinence syndrome: a prospective randomized clinical trial'. ( 26412406 )
2015
50
Pharmacokinetics of Oral Methadone in the Treatment of Neonatal Abstinence Syndrome: A Pilot Study. ( 26364984 )
2015

Variations for Neonatal Abstinence Syndrome

Expression for Neonatal Abstinence Syndrome

Search GEO for disease gene expression data for Neonatal Abstinence Syndrome.

Pathways for Neonatal Abstinence Syndrome

GO Terms for Neonatal Abstinence Syndrome

Cellular components related to Neonatal Abstinence Syndrome according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.77 COMT OPRD1 OPRK1 OPRM1 PNOC
2 neuron projection GO:0043005 9.43 OPRD1 OPRK1 OPRM1
3 perikaryon GO:0043204 9.32 OPRK1 OPRM1
4 dendrite GO:0030425 9.26 COMT OPRK1 OPRM1 PNOC
5 dendrite membrane GO:0032590 9.16 OPRD1 OPRM1
6 axon terminus GO:0043679 8.8 OPRD1 OPRK1 PNOC

Biological processes related to Neonatal Abstinence Syndrome according to GeneCards Suite gene sharing:

(show all 19)
id Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 9.88 OPRD1 OPRK1 OPRM1 PNOC
2 chemical synaptic transmission GO:0007268 9.67 OPRD1 OPRK1 OPRM1 PNOC
3 phospholipase C-activating G-protein coupled receptor signaling pathway GO:0007200 9.65 OPRD1 OPRK1 OPRM1
4 sensory perception of pain GO:0019233 9.63 OPRD1 OPRK1 OPRM1
5 adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway GO:0007193 9.61 OPRD1 OPRK1 OPRM1
6 response to ethanol GO:0045471 9.58 OPRK1 OPRM1
7 female pregnancy GO:0007565 9.57 COMT PNOC
8 locomotory behavior GO:0007626 9.56 OPRK1 OPRM1
9 G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.55 OPRD1 OPRM1
10 response to cocaine GO:0042220 9.54 OPRK1 OPRM1
11 response to radiation GO:0009314 9.52 OPRK1 OPRM1
12 response to morphine GO:0043278 9.51 OPRK1 OPRM1
13 eating behavior GO:0042755 9.5 OPRD1 OPRK1 OPRM1
14 estrous cycle GO:0044849 9.49 OPRK1 OPRM1
15 neuropeptide signaling pathway GO:0007218 9.46 OPRD1 OPRK1 OPRM1 PNOC
16 sensory perception GO:0007600 9.43 OPRK1 OPRM1 PNOC
17 adenylate cyclase-inhibiting opioid receptor signaling pathway GO:0031635 9.4 OPRK1 OPRM1
18 opioid receptor signaling pathway GO:0038003 9.13 OPRD1 OPRK1 OPRM1
19 regulation of sensory perception of pain GO:0051930 8.92 COMT OPRD1 OPRK1 OPRM1

Molecular functions related to Neonatal Abstinence Syndrome according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 G-protein coupled receptor activity GO:0004930 9.33 OPRD1 OPRK1 OPRM1
2 neuropeptide binding GO:0042923 9.13 OPRD1 OPRK1 OPRM1
3 opioid receptor activity GO:0004985 8.8 OPRD1 OPRK1 OPRM1

Sources for Neonatal Abstinence Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....